The pursuit of drug candidates for neurological diseases including Parkinson' Disease (PD), Alzheimer's disease (AD), Spinal Cord Injury (SCI), and Neural Tube Defects (NTD), etc, is deemed as challenging due to the undesirable side effects of many drugs available on the market. Despite the imminent approval of new drug candidates like galanthamine, zuranolone, and emraclidine, there is still a lack of attention to drug discovery derived from herbal medicine, polypeptides, and oligopeptides.
This Research Topic seeks to consolidate research findings concerning the discovery of drug candidates from herbal medicine, polypeptides, and oligopeptides for the treatment of neurological diseases. The primary objective is to report on pharmaceutical analysis, analytical techniques and methods, new drug delivery methods, pharmacology, metabolism, and organic synthesis of drug candidates. By addressing gaps in knowledge and identifying recent breakthroughs, our Research Topic aims to elucidate the potential of herbal medicine and polypeptides in neurological disease treatment.
Scope and Information for Authors: This Research Topic encourages to contribute manuscripts focusing on various themes, including but not limited to:
• Identifying drug candidates within herbal medicine, polypeptides, or oligopeptides for the treatment of neurological diseases.
• Elucidating the biological mechanisms underlying the neurological diseases treatment of herbal medicine, polypeptides, or polypeptides.
• Presenting novel methods for the separation of drug candidates, enhancing our ability to investigate their effects.
• Constructing/improving the drug delivery methods for passing the blood-brain barrier.
This Research Topic serves as a platform to disseminate cutting-edge research and expand our understanding of these promising therapeutic strategies. We invite the authors to contribute Original Research, Perspective, Review, Clinical Trial, Opinion, Commentary, and Case Report to this Research Topic.
Please Note: All the manuscripts submitted to this project will be peer-reviewed and need to fully comply with the
Four Pillars of Best Practice in Ethnopharmacology (you can freely download the full version
here) and the ConPhyMP statement: Front. Pharmacol. 13:953205. https://doi.org/10.3389/fphar.2022.953205). You need to check your MS using the ConPhyMP tool, see https://ga-online.org/best-practice// It is essential that the studies focus on specific, pharmacognstically well-defined preparations and these preparations must be characterised chemically if experimental studies are included. Purely in silico analyses of specific preparations using network analysis or docking studies are only considered if a detailed body of novel experimental pharmacological data are included.